Shanghai Changzheng Hospital

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This phase 2 trial tests a combination of three drugs—carfilzomib, cyclophosphamide, and dexamethasone—in 20 people newly diagnosed with POEMS syndrome, a rare disorder affecting nerves and blood. The goal is to see if the regimen can reduce abnormal proteins and improve symptoms…

This early study is testing whether a single injection of special stem cells (hiSCs) into the knee joint is safe and can reduce pain and swelling in people with rheumatoid arthritis. Only 15 adults with active knee arthritis will take part. The main goal is to check for side effe…

This Phase II trial tests a combination of two drugs, anlotinib and sintilimab, as a first treatment for advanced colorectal cancer that has spread but not to the liver. The goal is to shrink tumors and control the disease without using standard chemotherapy. About 37 patients wh…

This study tests whether a gut-acting antibiotic called rifaximin-α can reduce liver fat in people with metabolic fatty liver disease (MASLD). About 60 adults will take either the drug or just follow diet and exercise advice for 24 weeks. The goal is to see if the drug safely low…

This study is testing whether taking pancreatic enzyme supplements (Creon) can improve blood sugar control and digestive function in people with chronic pancreatitis who have trouble digesting food. Researchers will monitor 80 participants over time to see how their glucose level…

This early-stage trial is testing whether the antibiotic rifaximin can reduce liver fat in people with metabolic fatty liver disease. About 40 adults will take rifaximin pills three times daily for up to 48 weeks, while maintaining diet and exercise. The main goal is to see if li…

This study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammati…

This study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 is an antibody that blocks a protein involved in the disease. The goal is to see if it improves eye symptoms …

This study tests a two-step treatment for people with moderate-to-severe thyroid eye disease (TAO) that is still active. First, patients receive high-dose steroids, then a newer drug called tetuzumab (IBI311) that blocks a growth factor receptor. The goal is to reduce bulging eye…

This study looks at whether the amount of iron in tears is linked to how severe dry eye disease is. Researchers will collect tear samples from 52 people with and without dry eye and compare iron levels to standard eye tests and symptom scores. The goal is to find a new way to dia…

This study uses a non-invasive eye tracker to measure how well people with Thyroid-Associated Ophthalmopathy (TAO) can move their eyes and pay attention to faces. Researchers will compare 100 participants, including patients and healthy volunteers, to see if the disease causes me…

This study follows 4,094 adults in Shanghai who were part of an earlier health survey. Researchers will track them for up to 10 years to see how heart disease, kidney problems, and metabolic conditions like diabetes and obesity develop and interact. The goal is to better understa…